Low Molecular Weight Heparin and Its Clinical Use: Journal
Read Online

Low Molecular Weight Heparin and Its Clinical Use: Journal Haemostasis, Vol. 16, 1985 (Low Molecular Weight Heparin & Its Clinical Use) by Meyer M. Samama

  • 473 Want to read
  • ·
  • 86 Currently reading

Published by S. Karger AG (Switzerland) .
Written in English


  • Hematology,
  • Medical / Nursing

Book details:

The Physical Object
Number of Pages124
ID Numbers
Open LibraryOL12929717M
ISBN 103805542305
ISBN 109783805542302

Download Low Molecular Weight Heparin and Its Clinical Use: Journal


Low-molecular-weight heparin (LMWH) is a class of anticoagulant medications. They are used in the prevention of blood clots and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.. Heparin is a naturally occurring polysaccharide that inhibits coagulation, the process that leads to ilability: %. The low‐molecular‐weight heparin products dalteparin, enoxaparin and tinzaparin are very similar but not identical. The methods used to chemically prepare these commercially available products differ, and a number of studies have shown distinct differences in their in vitro and in vivo pharmacology. Unfortunately, only a few studies have directly compared different low‐molecular heparins Cited by: The more predicable anticoagulant effect of low molecular weight heparin (LMWH) makes it is an attractive agent for use in this clinical situation but there are limited data relating to its safety and efficacy. In , Oran and co-workers 3 reviewed published case reports and case series of LMWH use in pregnant women with MHV. The overall rate Cited by: 3.   Low-molecular weight heparin is increasingly replacing unfractionated heparin (UFH) as the treatment of choice in this indication. This review focuses on the role of LMWH in the management of thrombotic disease in pregnancy and presents a summary of the ACCP guidelines on the use of LMWH in this indication.

A number of such products, low molecular weight heparins (LMWH) were patented and introduced as new drugs during the ensuing of 20 years. Each LMWH had to be given a clinical trial against standard heparin for the several thromboembolic disorders for which heparin was the standard of care.   Heparins are anticoagulant drugs currently used for the prophylaxis and therapy of venous thromboembolism and are classified according to their molecular weight. 36 Heparin reversibly binds antithrombin III and amplifies its subsequent inhibitory effect on activated factor X and thrombin (factor Xa). 37, 38 Only unfractionated heparin.   Background: The antitumor and antimetastatic properties of heparins have not been tested in patients with early-stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin impacts the survival of patients with resected non-small cell lung cancer (NSCLC) was investigated. Patients and Methods: Patients with completely resected stage I, II or IIIA NSCLC were .   The team wrote, “In-vitro spiking of COVID samples from patients in intensive care unit with low molecular weight heparin failed to recover the anti-Xa level as would have been predicted.”.

A number of low molecular weight heparin (LMWH) products are available for clinical use and although all share a similar mechanism of action, they are classified as distinct drugs because of the different depolymerisation processes of the native heparin resulting in substantial pharmacokinetic and pharmacodynamics differences. While enoxaparin has been extensively investigated, little.   Prophylactic anticoagulation via low molecular weight heparin (LMWH) (eg, enoxaparin 40 mg SC) should be given for anticoagulation in moderate (once time per day) to severe patients (two times per day) in view of the high risk of thromboembolism. Comorbidities such as associated hypertension, hypothyroidism or diabetes should be managed. This article describes the pharmacology of approved parenteral anticoagulants. These include the indirect anticoagulants, unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs), fondaparinux, and danaparoid, as well as the direct thrombin inhibitors hirudin, bivalirudin, and argatroban. UFH is a heterogeneous mixture of glycosaminoglycans that bind to antithrombin via a unique. Journal Info. About the Journal; Advertising and Business; AJN Photo Exhibit: Faces of Caring Low-Molecular-Weight Heparin or Heparinoids vs. Unfractionated Heparin in Acute Ischemic Stroke. Newsom, Cresilda T. DNP, MSN, RN, CPAN these clinical trials did not provide reliable evidence on the risk–benefit for each type of heparin.